Montgomery–Asberg Depression Rating Scale (MADRS) and Hamilton Anxiety Rating Scale (HAM-A). RA-pts with ADD were divided into the following treatment groups: 1 – cDMARDs (n=39), 2 – cDMARDs + PPT (sertraline or mianserine) (n=43), 3 – cDMARDs + bDMARDs (n=32), 4 – cDMARDs + bDMARDs + PPT (sertraline or mianserine) (n=9). Biologics treatment duration varied from 1 to 6 years, antidepressants – from 6 to 96 weeks.

Results: HAQ scores were high in all 4 groups at baseline and after five years remained high in all groups except group 2 with the lowest endpoint scores among 4 groups (table 1). To measure changes in HAQ scores between groups we compared the differences between baseline and endpoint HAQ scores (Δ HAQ = endpoint HAQ – baseline HAQ) (table 2). The table shows an improvement in HAQ scores in groups 2 and 3, no significant changes in group 4 and a worsening of HAQ scores in group 1. HAQ scores in groups 2 and 3 significantly improved compared to group 1.

Table 1 Mean HAQ scores in RA patients with ADD at baseline and after 5 years, by groups.

Groups	At baseline (n=128)	After 5 years (n=83)	P between time points
1 (cDMARDs), n=39	1,39±0,75	1,61±0,7	>0,05
2 (cDMARDs + PPT), n=43	1,42±0,9	0,85±0,66	0,011
3 (cDMARDs + bDMARDs), n=32	1,58±0,76	1,36±0,71	>0,05
4 (cDMARDs + bDMARDs + PPT), n=9	1,38±0,83	1,49±0,26	>0,05
P between groups	>0,05	P ₂₋₁ <0,001; P ₂₋₃ =0,023 P ₂₋₄ =0,015	

Table 2. Differences between baseline and 5-years endpoint HAQ scores, by groups

	cDMARDs, n=24	cDMARDs + PPT, n=29	cDMARDs + bDMARDs, n=21	cDMARDs + bDMARDs + PPT, n=9	
	1	2	3	4	p
Δ HAQ	0,23±0,49	-0,3±0,42	-0,28±0,94	0±0,82	P ₁₋₂ =0,002; P ₁₋₃ =0,033

Conclusion: Functional abilities measured by HAQ scores significantly improved in RA-patients with ADD receiving cDMARDs in combination with bDMARDs or PPT compared to cDMARDs only. The lowest HAQ scores were observed in patients receiving cDMARDs in combination with PPT.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.367

Rheumatoid arthritis - prognosis, predictors and outcome II

OP0216

DEVELOPMENT AND VALIDATION OF PATIENT-LEVEL PREDICTION MODELS FOR ADVERSE HEALTH OUTCOMES AMONGST ADULT RA PATIENTS INITIATING FIRST-LINE TREATMENT OF METHOTREXATE MONOTHERAPY: A MULTINATIONAL REAL-WORLD COHORT ANALYSIS INCLUDING 164,735 SUBJECTS

C. Yang¹, R. Williams², J. Swerdel³, M. Jani⁴, T. Duarte-Salles⁵, K. Chatzidionysiou⁶, D. Prieto-Alhambra⁷, P. Ryan⁸, P. Rijnbeek⁹ on behalf of 'European Health Data and Evidence Network (EHDEN) RA Research Group'. ¹Department of Medical Informatics EMC, Rotterdam, Netherlands; ²Department of Medical Informatics Erasmus MC, Rotterdam, Netherlands; ³Janssen Research and Development, New Jersey, United States of America; ⁴Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom; ⁵Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain; ⁶Dep of Medicine, Solna, Rheum Unit, Karolinska Institutet, Stockholm, Sweden; ⁷University of Oxford, NDORMS, Oxford, United Kingdom; ⁸Johnson & Johnson, New Jersey, United States of America; ⁹Erasmus University, Department of Medical Informatics, Rotterdam, Netherlands

Background: EULAR guidelines recommend the early initiation of methotrexate (MTX) monotherapy as soon as possible after the diagnosis of rheumatoid arthritis (RA). Evaluating patient-level risks for adverse outcomes after MTX initiation would allow clinicians to provide more personalised care.

Objectives: To develop and validate patient-level prediction models for adverse health outcomes including leukopenia, pancytopenia, infection (serious, opportunistic, all), cardiovascular disease (CVD) (myocardial infarction (MI), stroke),

and cancer (breast, colorectal, uterus) in adult RA patients initiating first-line treatment of MTX monotherapy

Methods: Health data from claims and electronic health records were used including patients from 7 European countries (Spain, Estonia, Netherlands, Belgium, Germany, France, and the UK), the United States of America, Australia, and Japan. All RA patients initiating first-line treatment of MTX monotherapy with at least one year of prior observation were included. Prediction models for the outcomes were developed for a time at risk of 3 months (infections, leukopenia, pancytopenia), 2 years (MI and stroke), and 5 years (cancers) on the Optum® De-Identified Clinformatics® Data Mart Database. Models were developed using LASSO logistic regression and were evaluated using the area under the receiver operator characteristic curve (AUROC) for discrimination and graphically assessed for calibration. The models were externally validated on all other databases.

Results: A total of 21,307 subjects were used for training and validated against 143,427 patients from 14 sites. MI (AUROC internal 0.77, AUROC external ranging from 0.49 to 0.78), stroke (AUROC internal 0.78, AUROC external ranging from 0.68 to 0.79) and serious infection (AUROC internal 0.75, AUROC external ranging from 0.63 to 0.79) had good predictive validity [Table 1]. Discrimination for all other outcomes was lower, with all AUC<0.7 in internal validation. For detailed results see: <https://data.ohdsi.org/ehdenRaPrediction/>

Table 1. Internal (Optum) and external validation results: AUC ROC for discrimination

Database	Acute MI within 2y	Stroke within 2y	Serious Infection within 3m
Optum (internal)	0.77	0.78	0.75
PanTher	0.76	0.78	0.74
IQVIA_AMBEMR	0.76	0.72	
CCAE	0.73	0.73	0.66
IQVIA_GERMANY	0.64	0.70	
IQVIA_THIN	0.62	0.65	
MDCR	0.68	0.68	0.67
IQVIA_HOSPITAL	0.67	0.63	0.61
MDCD	0.72	0.79	0.63
JMDC	0.49	0.75	0.71
IQVIA_LPDFRANCE	0.69		
Estonia	0.67	0.77	0.82
IQVIA_AUS	0.58		
IPCI	0.68		
SIDIAP	0.65	0.75	

Conclusion: Clinical tools were developed that successfully identify subjects at risk of MI, stroke and serious infection at the initiation of first-line MTX therapy. The developed algorithms had good transportability and generally, the models with high AUROC had adequate internal calibration although some external validations show they could benefit from recalibration. For short-term opportunistic and all infections, as well as 5-year cancer models, we were unable to achieve a high enough AUROC to warrant validating externally.

Disclosure of Interests: Cynthia Yang: None declared, Ross Williams: None declared, Joel Swerdel Shareholder of: J&J shares, Grant/research support from: Full-time employment salary from Janssen, Consultant of: Janssen employee, Employee of: Janssen, Paid instructor for: Janssen employee, have instructed at conferences, Speakers bureau: Janssen employee, have spoken at conferences, Meghna Jani Speakers bureau: Grifols, Talita Duarte-Salles: None declared, Katerina Chatzidionysiou Consultant of: AbbVie, Pfizer, Lilly, Daniel Prieto-Alhambra Grant/research support from: Professor Prieto-Alhambra has received research Grants from AMGEN, UCB Biopharma and Les Laboratoires Servier, Consultant of: DPA's department has received fees for consultancy services from UCB Biopharma, Speakers bureau: DPA's department has received fees for speaker and advisory board membership services from Amgen, Patrick Ryan: None declared, Peter Rijnbeek: None declared

DOI: 10.1136/annrheumdis-2020-eular.3606

OP0217

INVOLVEMENT OF LARGE JOINTS AT DISEASE PRESENTATION IS ASSOCIATED WITH DIVERSE HISTOPATHOLOGICAL FEATURES AND CLINICAL OUTCOMES IN EARLY RHEUMATOID ARTHRITIS

F. Rivelles¹, F. Humby¹, G. Lliso Ribera¹, A. Nerviani¹, E. Sciacca¹, G. Giorli¹, R. Hands¹, L. Fossati-Jimack¹, G. Thorburn¹, M. Lewis¹, C. Pitzalis¹.

¹Queen Mary University of London, Centre for Experimental Medicine and Rheumatology, London, United Kingdom

Background: The involvement of large joints at disease presentation in early Rheumatoid Arthritis (RA) has been associated with severe disease activity. At the same time, the clinical heterogeneity of RA is known to be mirrored by heterogeneity of synovial inflammation, with specific histological patterns (pathotypes)